Jaap Jan Boelens
Pediatric Hematology-Oncology · New York, NYNPI 1902466949
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.5%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Sobi, Inc accounts for 60.2% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2024 at $126,878 and has fallen 73.7% since, to $33,349 in 2025. Among pediatric hematology-oncology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 279 payments — averaging $1085.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sobi, Inc$182K
- Sanofi-aventis U.S. LLC$72K
- Omeros Corporation$17K
- Sanofi$13K
- AstraZeneca$8K
- Merck$7K
- plus $4K from 7 others
Across 23 payments — averaging $94,941 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1.9M
- Sanofi-aventis U.S. LLC$227K
- Omeros Corporation$19K
What the payments were for
- Consulting fees$62,86021%
- Speaking & faculty fees$168,27456%
- Travel & lodging$63,29521%
- Food & beverage$8,4443%
- Education$810%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sobi, Inc | 224 | $182,405 |
| Sanofi-aventis U.S. LLC | 25 | $71,789 |
| Omeros Corporation | 9 | $16,778 |
| Sanofi | 5 | $12,751 |
| AstraZeneca | 2 | $8,267 |
| Merck | 2 | $7,420 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $1,500 |
| National Marrow Donor Program | 4 | $1,398 |
| Novartis | 2 | $242 |
| Genetix Biotherapeutics Inc | 2 | $168 |
| Medexus Pharma, Inc. | 1 | $168 |
| Orchard Therapeutics North America | 1 | $44 |
| Vertex | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Gamifant$178,492
- THYMOGLOBULIN$43,039
- REZUROCK$23,536
- narsoplimab$9,505
- ULTOMIRIS$8,267
- SARCLISA$4,633
- Entyvio$1,500
- LYFGENIA$144
How this compares
$302,954 in reported general payments places this provider in the 95th percentile of 196 pediatric hematology-oncology providers in New York.
See all pediatric hematology-oncology providers in New York →
Other pediatric hematology-oncology in New York
- Sujit ShethNew York$359K
- James BusselNew York$204K
- Saara KavianyNew York$144K
- Gary BrittenhamNew York$137K
- James FerraraNew York$118K
- John LevineNew York$98K
- Nai-Kong CheungNew York$86K
- Andrew HarrisNew York$85K
- Joseph OvedNew York$77K
- Catherine McGuinnNew York$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.